Ipsen Acquisition Epizyme 2022 Investor Call

Ipsen investor and analyst call presentation dated June 27, 2022, discussing the acquisition of Epizyme, Inc. The call features leadership including CEO David Loew, CFO Aymeric Le Chatelier, and Head of R&D Howard Mayer addressing the strategic acquisition and its implications for the pharmaceutical company's portfolio.